Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (XENE) reported a third-quarter net loss of $110.4 million while advancing azetukalner toward potential commercialization for focal seizures. The loss widened from $90.9 million a year earlier. Cash, cash equivalents and marketable securities totaled $1,153.5 million at September 30, 2026, versus $586.0 million at December 31, 2025; Xenon expects funding to last into 2029.
An FDA application for azetukalner in focal seizures was submitted in September 2026. Phase 3 X-NOVA2 enrollment in major depressive disorder finished at approximately 360 patients, with results now expected in December 2026. New enrollment in ongoing depression and bipolar depression studies remains voluntarily paused; enrolled patients remain active. Xenon plans the Phase 3b/4 X-FIRST epilepsy study for Q1 2027 and expects Phase 2 acute-pain studies of XEN1701 and XEN1120 to begin in H1 2027 following positive Phase 1 data.
Xenon Pharmaceuticals (Nasdaq: XENE) will present at four investor conferences through fireside chats in November and December 2026. The schedule includes Guggenheim in Boston on November 10, Stifel in New York on November 11, Jefferies in London on November 18, and Evercore in Coral Gables on December 1. Webcast information will be available on Xenon's investor website, with replays posted when available. Dates and times are subject to change.
Xenon Pharmaceuticals (XENE) will report third-quarter 2026 financial results and provide a business update after U.S. markets close on November 9, 2026. The company presentation is scheduled for 4:30 p.m. EST. A live webcast will be available through the Investors section of Xenon's website, with a replay posted afterward. Dates and times are subject to change.
Xenon Pharmaceuticals (Nasdaq: XENE) granted equity inducement awards to new non-officer employees, effective October 29, 2026.
The awards cover 24,250 share options and 14,250 restricted share units (RSUs) for nine employees. The options have an exercise price of $37.54 per common share, equal to the closing share price on the grant date. Both award types vest over four years, subject to continued service. The Compensation Committee approved the grants as material inducements to employment under Nasdaq Listing Rule 5635(c)(4), through the company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Phase 1 results supporting planned advancement of XEN1701 and XEN1120 into acute pain studies. The company expects to initiate both Phase 2 proof-of-concept studies in the first half of 2027; designs are being finalized.
For XEN1701, sampling and modeling indicated proposed Phase 2 doses maintained more than 75% occupancy of the NaV1.7 pain-signaling target in peripheral and central nervous systems with twice-daily dosing. XEN1120 exceeded exposure levels predicted effective by animal models. Neither study reported treatment-related, dose-limiting adverse events or adverse events leading to discontinuation. XEN1120 adverse events included tachycardia, dizziness and somnolence. Separate monkey studies found reduced evoked pain with compounds comparable to each candidate; XEN1120 also reduced acute-phase pain in mice.
Xenon Pharmaceuticals (Nasdaq: XENE) granted equity inducement awards to eight new non-officer employees, effective October 1, 2026, to support their hiring.
The awards comprise 17,850 share options and 10,500 restricted share units (RSUs). The options have an exercise price of $38.93 per common share, equal to the closing share price on the grant date. Both award types vest over four years, subject to continued service. The board’s Compensation Committee approved the grants under the company’s Amended and Restated 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals (XENE) will present at the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit in a virtual fireside chat on Wednesday, September 23, from 2:00 to 2:25 pm ET.
Details and webcast access will be available in the Investors section of Xenon’s website, with replays posted after the event, and the company notes that the listed date and time are subject to change. Xenon highlights its lead molecule, azetukalner, a KV7 potassium channel opener in late-stage clinical development for epilepsy, major depressive disorder and bipolar depression, and mentions additional KV7 and NaV1.7 programs in Phase 1 for pain.
Xenon Pharmaceuticals (XENE) has submitted a New Drug Application (NDA) to the U.S. FDA for azetukalner as adjunctive treatment for focal seizures in epilepsy, supported by Phase 2b X‑TOLE and Phase 3 X‑TOLE2 trials. Across both randomized, double-blind, placebo-controlled studies, all four azetukalner doses showed statistically significant reductions from baseline in monthly seizure frequency versus placebo, with a generally well-tolerated and consistent safety profile aligned with more than 1,500 patient‑years of exposure data.
Ongoing Phase 3 epilepsy trials X‑TOLE3 (focal seizures) and X‑ACKT (primary generalized tonic-clonic seizures) continue enrolling. In psychiatry, Xenon has completed enrollment in the X‑NOVA2 MDD study at about 360 patients and now expects topline data in Q1 2027. The company has voluntarily paused enrollment of new patients in its MDD and bipolar depression studies, after reviewing neuropsychiatric adverse events, while continuing treatment of currently enrolled participants and evaluating dose modifications.
Xenon Pharmaceuticals (XENE) plans to present at the Wells Fargo Healthcare Conference in Boston, MA, via a fireside chat scheduled for Wednesday, September 9, from 11:00 to 11:30 am ET.
Details and a live webcast link will be available in the Investors section of Xenon’s website, with a replay posted after the event, subject to possible schedule changes.
Xenon Pharmaceuticals (Nasdaq: XENE) granted equity inducement awards to five new non-officer employees under Nasdaq Listing Rule 5635(c)(4), effective August 27, 2026. The awards consist of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs), approved by the board’s Compensation Committee.
The options have a $61.93 exercise price, equal to the August 27, 2026 closing price, a 10-year term, and vest over four years (25% at one year, then monthly thereafter). RSUs vest 25% annually over four years. All grants are made under the Amended and Restated 2025 Inducement Equity Incentive Plan.